AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based ...

On a per-share basis, the Cambridge, Britain-based company said it had profit of 93 cents. Earnings, adjusted for non-recurring costs, came to $1.24 per share. The results topped Wall Street ...

AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry.

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of ...

Pharmaceutical giant AstraZeneca is making "excellent progress" toward its ambition of hitting $80bn in revenue by 2030, following a strong first quarter.

LONDON (Reuters) -The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance ...

The resounding silence from UVa President Jim Ryan and the Board of Visitors suggests they condone attacks on their health ...

European stocks were set for a mixed open on Tuesday, with results out from HSBC, Lufthansa, Volvo Cars, Adidas, BP, ...